Calendar Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
359.27 ^USD	+0.00%		-9.80%	-9.65%

01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing	MT

Chart calendar Alnylam Pharmaceuticals, Inc.

f1df0c94fabc0af.bpURrw0zWn16WxGr8xFtSwGxfI7uY8RyT0zy-ZjkGgM.KN96n0EGBQdKAXf0kFQJD2f6D_jdGpAiHDq0of-df0gK_3ydYgATFhURRA~67b43a104e236690a56ae781191a12e3

Upcoming events on Alnylam Pharmaceuticals, Inc.

11/02/2026	Q4 2025 Earnings Release (Projected)	Add to your calendar Google Apple ICS format
29/04/2026	Q1 2026 Earnings Release (Projected)	Add to your calendar Google Apple ICS format
29/07/2026	Q2 2026 Earnings Release (Projected)	Add to your calendar Google Apple ICS format
28/10/2026	Q3 2026 Earnings Release (Projected)	Add to your calendar Google Apple ICS format

Past events on Alnylam Pharmaceuticals, Inc.

12/01/2026	J.P. Morgan Healthcare Conference
19/11/2025	Jefferies Global Healthcare Conference
10/11/2025	UBS Global Healthcare Conference
30/10/2025	Q3 2025 Earnings Call
30/10/2025	Q3 2025 Earnings Release
23/09/2025	Bernstein Healthcare Forum
10/09/2025	Morgan Stanley Global Healthcare Conference
03/09/2025	Citi Biopharma Back to School Conference
31/08/2025	European Society of Cardiology Congress
31/08/2025	European Society of Cardiology Congress
30/08/2025	European Society of Cardiology Congress
30/08/2025	European Society of Cardiology Congress
30/08/2025	European Society of Cardiology Congress
12/08/2025	Canaccord Genuity Growth Conference
31/07/2025	Q2 2025 Earnings Call
31/07/2025	Q2 2025 Earnings Release
09/06/2025	Goldman Sachs Global Healthcare Conference
20/05/2025	European Society of Cardiology Heart Failure Congress
19/05/2025	European Society of Cardiology Heart Failure Congress
19/05/2025	European Society of Cardiology Heart Failure Congress

Annual results

Fiscal Period	December	2022	2023	2024	2025	2026	2027
Net sales Million USD	Released Forecast Spread	1 037 1 013 2.41%	1 828 1 827 0.1%	2 248 2 235 0.57%	3 777	5 515	7 111
EBITDA Million USD	Released Forecast Spread	-741 -646 -14.71%	-228 -250 8.91%	-120 -66,4 -81.11%	558	1 697	3 314
EBIT Million USD	Released Forecast Spread	-785 -813 3.38%	-282 -275 -2.6%	-177 -127 -39.16%	585	1 268	2 283
Earnings before Tax (EBT) Million USD	Released Forecast Spread	-1 127 -1 138 1%	-434 -437 0.72%	-377 -254 -48.31%	375	1 121	2 096
Net income Million USD	Released Forecast Spread	-1 131 -1 156 2.16%	-440 -441 0.12%	-278 -257 -8.18%	325	997	1 840
EPS USD	Released Forecast Spread	-9,30 -9,42 1.32%	-3,52 -3,53 0.29%	-2,18 -2,01 -8.49%	2,41	7,24	13,2
Announcement Date		23/02/23	15/02/24	13/02/25	-

Quarterly results

Fiscal Period	September	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales Million USD	Released Forecast Spread	494 427 15.84%	660 444 48.56%	501 527 -4.95%	593 581 2.16%	594 581 2.23%	774 662 16.79%	1 249 974 28.22%	1 162	1 245	1 378	1 511	1 674
EBITDA Million USD	Released Forecast Spread	-29,9 -123 75.76%	63,6 -115 155.56%	-62,9 -82,7 23.91%	-91,0 -56,1 -62.19%	32,5 -107 130.36%	-2,26 -9,87 77.16%	382 176 116.74%	144	272	344	448	820
EBIT Million USD	Released Forecast Spread	-43,4 -117 63.03%	48,6 -114 142.58%	-76,9 -98,9 22.24%	-105 -57,2 -83.86%	18,1 -102 117.8%	-16,2 -51,6 68.58%	368 126 192.8%	226	292	349	414	507
Earnings before Tax (EBT) Million USD	Released Forecast Spread	-63,6 -133 52.26%	-11,2 -136 91.8%	-109 -123 11.85%	-194 -67,0 -189.64%	-41,6 -130 67.91%	-35,4 -82,6 57.18%	239 70,5 239.2%	209	275	337	391	474
Net income Million USD	Released Forecast Spread	-65,9 -144 54.13%	-16,9 -135 87.49%	-112 -123 9.38%	-83,8 -80,0 -4.69%	-57,5 -121 52.4%	-66,3 -80,4 17.57%	251 61,9 305.72%	191	252	312	359	439
EPS USD	Released Forecast Spread	-0,52 -1,17 55.39%	-0,13 -1,09 88.09%	-0,87 -0,94 7.71%	-0,65 -0,59 -10.22%	-0,44 -1,01 56.22%	-0,51 -0,70 27.1%	1,84 0,55 236.13%	1,32	1,62	2,01	2,34	2,99
Announcement Date		02/05/24	01/08/24	31/10/24	13/02/25	01/05/25	31/07/25	30/10/25	-	-	-	-	-

Upcoming sector events for Alnylam Pharmaceuticals, Inc.

20/01/2026	DR. REDDY'S LABORATORIES LIMITED	Q3 2026 Earnings Release	Add to your calendar Google Apple ICS format
20/01/2026	HANALL BIOPHARMA CO., LTD.	Q4 2025 Earnings Release (Projected)	Add to your calendar Google Apple ICS format
21/01/2026	JOHNSON & JOHNSON	Q4 2025 Earnings Release	Add to your calendar Google Apple ICS format
21/01/2026	ALIVUS LIFE SCIENCES LIMITED	Q3 2026 Earnings Release	Add to your calendar Google Apple ICS format
21/01/2026	TORRENT PHARMACEUTICALS LIMITED	Q3 2026 Earnings Release (Projected)	Add to your calendar Google Apple ICS format
22/01/2026	LAURUS LABS LIMITED	Q3 2026 Earnings Release	Add to your calendar Google Apple ICS format
22/01/2026	GRANULES INDIA LIMITED	Q3 2026 Earnings Release	Add to your calendar Google Apple ICS format
27/01/2026	GLAND PHARMA LIMITED	Q3 2026 Earnings Release	Add to your calendar Google Apple ICS format
27/01/2026	JCR PHARMACEUTICALS CO., LTD.	Q3 2025 Earnings Release	Add to your calendar Google Apple ICS format
27/01/2026	PIRAMAL PHARMA LIMITED	Q3 2026 Earnings Release	Add to your calendar Google Apple ICS format

More events

Past sector events for Alnylam Pharmaceuticals, Inc.

16/01/2026	J. B. CHEMICALS & PHARMACEUTICALS LIMITED	Q3 2026 Earnings Release
15/01/2026	SUPRIYA LIFESCIENCE LIMITED	Q3 2026 Earnings Release (Projected)
12/01/2026	LOTUS PHARMACEUTICAL CO., LTD.	December 2025 Sales and Revenue Release
10/01/2026	SCINOPHARM TAIWAN, LTD.	December 2025 Sales and Revenue Release
09/01/2026	CALIWAY BIOPHARMACEUTICALS CO., LTD.	December 2025 Sales and Revenue Release
08/01/2026	BORA PHARMACEUTICALS CO., LTD.	December 2025 Sales and Revenue Release
08/01/2026	TILRAY BRANDS, INC.	Q2 2026 Earnings Release
08/01/2026	CENTER LABORATORIES, INC.	December 2025 Sales and Revenue Release
07/01/2026	TTY BIOPHARM COMPANY LIMITED	December 2025 Sales and Revenue Release
05/01/2026	HISAMITSU PHARMACEUTICAL CO., INC.	Q3 2025 Earnings Release